Immunotherapy and symptomatic radiation necrosis in patients with brain metastases treated with stereotactic radiation

JAMA Oncology

Volumn 4, Issue 8, 2018, Pages 1123-1124

  Martin, Allison M ^d   Cagney, Daniel N ^d   Catalano, Paul J ^a,b   Alexander, Brian M ^d   Redig, Amanda J ^c   Schoenfeld, Jon D ^d   Aizer, Ayal A ^d  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB;

ADULT; BRAIN METASTASIS; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; MELANOMA; NON SMALL CELL LUNG CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; RADIATION NECROSIS; RENAL CELL CARCINOMA; RETROSPECTIVE STUDY; STEREOTACTIC TREATMENT; ADVERSE EVENT; BRAIN TUMOR; FOLLOW UP; IMMUNOLOGY; IMMUNOTHERAPY; KIDNEY TUMOR; LUNG TUMOR; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; RADIATION INJURY; RADIOSURGERY; SURVIVAL RATE;

BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; RADIATION INJURIES; RADIOSURGERY; SURVIVAL RATE;

EID: 85044149736     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2017.3993     Document Type: Letter

References (6)

1. Giglio P, Gilbert MR. Cerebral radiation necrosis. Neurologist. 2003;9(4): 180-188.
2. Chasset F, Pages C, Biard L, et al. Single-center study under a French Temporary Authorization for Use (TAU) protocol for ipilimumab in metastatic melanoma: negative impact of baseline corticosteroids. Eur J Dermatol. 2015;25 (1):36-44.
3. Goldberg SB, Gettinger SN, Mahajan A, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016;17(7):976-983.
4. Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012;13(5):459-465.
5. Tawbi HA-H, Forsyth PAJ, Algazi AP, et al. Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: results of the phase II study CheckMate 204. J Clin Oncol. 2017;35(suppl 15):9507-9507.
6. Long GV, Atkinson V, Menzies AM, et al. A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): The Anti-PD1 Brain Collaboration (ABC). J Clin Oncol. 2017;35(suppl 15):9508-9508.